ClassIndications
- Acute and maintenance treatment of schizophrenia and related psychotic disorders
- Acute treatment of manic or mixed episodes of bipolar 1 disorder
- Psychotic symptoms in dementia
- Intramuscular olanzapine is indicated for the rapid control of agitated patients
Administration/Absorption
- Oral
- 40% of the dose metabolized before reaching the systemic circulation
- IM
Dosage
Distribution
- 93% protein bound
- VOD 1000 L
Mechanism
- Combination of antagonism at:
- D2 receptors in the mesolimbic pathway
- Relieves positive symptoms
- 5HT2A receptors in the frontal cortex
- Relieves negative symptoms
Excretion
- Metabolized by the cytochrome P450 system isoenzymes 1A2 and 2D6
- Only 7% excreted unchanged in urine
- Half life 21 - 54 hr
Side effects
Interactions
Contraindications
|
|
